Personal information

Countries

Switzerland

Activities

Collapse all

Employment (2)

Inselspital Bern Universitätsklinik für Radio-Onkologie: Bern, BE, CH

2013-01-01 to present | Group Leader (Radiation Oncology)
Employment
Source: Self-asserted source
Michaela Medova

University of Bern: Bern, CH

2011-01-01 to 2012-12-01 | Postdoctoral Fellow (Department of Clinical Research)
Employment
Source: Self-asserted source
Michaela Medova

Education and qualifications (4)

University of Bern: Bern, CH

2018-06-01 to present | Privatdozent (PD) (Medical Faculty)
Qualification
Source: Self-asserted source
Michaela Medova

University of Bern: Bern, CH

2006-12-01 to 2010-12-10 | Ph.D. (Department of Clinical Research)
Education
Source: Self-asserted source
Michaela Medova

Comenius University: Bratislava, SK

2001-09-01 to 2006-06-19 | MSc. (Biophysics)
Education
Source: Self-asserted source
Michaela Medova

Comenius University: Bratislava, SK

2001-09-10 to 2006-06-02 | MSc. (Journalism)
Education
Source: Self-asserted source
Michaela Medova

Funding (10)

Adaptive Mechanisms of Receptor Tyrosine Kinases in Brain Development

2025-02-01 to 2029-01-31 | Grant
Swiss National Science Foundation (Bern, CH)
URL: https://app.dimensions.ai/details/grant/grant.14057643
GRANT_NUMBER: 10000884
Source: Self-asserted source
Michaela Medova via DimensionsWizard

Impact of Ser1016 phosphorylation, a newly identified site on the MET receptor tyrosine kinase, on MET-mediated physiologic and oncogenic signaling

2020-11-01 to 2024-10-31 | Grant
Swiss National Science Foundation (Bern, CH)
URL: https://app.dimensions.ai/details/grant/grant.9525954
GRANT_NUMBER: 197870
Source: Self-asserted source
Michaela Medova via DimensionsWizard

Installing a Hyperion CyTOF mass cytometry platform for high-dimensional single cell analysis at the University of Bern

2019-10-01 to 2021-11-30 | Grant
Swiss National Science Foundation (Bern, CH)
URL: https://app.dimensions.ai/details/grant/grant.8712581
GRANT_NUMBER: 183501
Source: Self-asserted source
Michaela Medova via DimensionsWizard

SciBmd Toxicity

2019-06 to 2021-09 | Grant
Innosuisse - Schweizerische Agentur für Innovationsförderung (Bern, CH)
GRANT_NUMBER:

34818.1 IP-LS
Source: Self-asserted source
Michaela Medova

Panomic-based characterization of the role of Ser1016 phosphorylation, a newly identified site on the MET receptor tyrosine kinase, in MET-mediated oncogenic signaling

2017-01 to 2019-12 | Grant
Stiftung für klinisch-experimentelle Tumorforschung (Muri bei Bern, CH)
Source: Self-asserted source
Michaela Medova

MET inhibition-related tumor radiosensitization under hypoxic conditions

2016-01 to 2016-12 | Grant
Stiftung zur Krebsbekämpfung (Zürich, CH)
Source: Self-asserted source
Michaela Medova

Impact of PI3K mutations on MET receptor tyrosine kinase targeting in head and neck cancer

2015-01 to 2016-12 | Grant
Bernische Krebsliga (Bern, CH)
Source: Self-asserted source
Michaela Medova

Characterization of a novel putative ATM/ATR/DNA-PK phosphorylation site on the MET receptor tyrosine kinase

2013 to 2016 | Grant
Werner und Hedy Berger-Janser Stiftung (Bern, CH)
Source: Self-asserted source
Michaela Medova

Role of MET signaling in mediating tumor radioresistance under hypoxic conditions

2012 to 2014 | Grant
Stiftung für klinisch-experimentelle Tumorforschung (Bern, CH)
Source: Self-asserted source
Michaela Medova

The relevance of p53 status to the response of tumor cells to MET inhibitors and to their radiosensitization via MET targeting

2012 to 2012 | Grant
Ruth und Albert Scherbarth Stiftung (Bern, CH)
Source: Self-asserted source
Michaela Medova

Works (49)

Ubiquinol-mediated suppression of mitochondria-associated ferroptosis is a targetable function of lactate dehydrogenase B in cancer.

Nature communications
2025-03 | Journal article
DOI: 10.1038/s41467-025-57906-3
PMID: 40090955
PMC: PMC11911438
Contributors: Deng H; Zhao L; Ge H; Gao Y; Fu Y; Lin Y; Masoodi M; Losmanova T; Medová M; Ott J et al.
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

HPV and p53 Status as Precision Determinants of Head and Neck Cancer Response to DNA-PKcs Inhibition in Combination with Irradiation.

Molecular cancer therapeutics
2025-02 | Journal article
DOI: 10.1158/1535-7163.mct-23-0794
PMID: 39513374
PMC: PMC11791480
Contributors: Hayrapetyan L; Roth SM; Quintin A; Hovhannisyan L; Medo M; Riedo R; Ott JG; Albers J; Aebersold DM; Zimmer Y et al.
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

A comprehensive comparison of tools for fitting mutational signatures.

Nature communications
2024-11 | Journal article
DOI: 10.1038/s41467-024-53711-6
PMID: 39487150
PMC: PMC11530434
Contributors: Medo M; Ng CKY; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Inhibition of LDHB suppresses the metastatic potential of lung cancer by reducing mitochondrial GSH catabolism.

Cancer letters
2024-11 | Journal article
DOI: 10.1016/j.canlet.2024.217353
PMID: 39615645
Contributors: Ge H; Malsiu F; Gao Y; Losmanova T; Blank F; Ott J; Medová M; Peng RW; Deng H; Dorn P et al.
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network.

Cancer research communications
2024-07 | Journal article
DOI: 10.1158/2767-9764.crc-23-0370
PMID: 38957115
PMC: PMC11288008
Contributors: Poliaková Turan M; Riedo R; Medo M; Pozzato C; Friese-Hamim M; Koch JP; Coggins SA; Li Q; Kim B; Albers J et al.
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

A DNA-PK phosphorylation site on MET regulates its signaling interface with the DNA damage response

Oncogene
2023-06-23 | Journal article | Author
DOI: 10.1038/s41388-023-02714-6
Part of ISSN: 0950-9232
Part of ISSN: 1476-5594
Contributors: Jonas Koch; Selina M. Roth; Aurélie Quintin; Jacopo Gavini; Eleonora Orlando; Rahel Riedo; Chiara Pozzato; Liana Hayrapetyan; Ruedi Aebersold; Deborah M. Stroka et al.
Source: Self-asserted source
Michaela Medova

Tumour mutations in long noncoding RNAs enhance cell fitness

Nature Communications
2023-06-08 | Journal article
DOI: 10.1038/s41467-023-39160-7
Part of ISSN: 2041-1723
Contributors: Roberta Esposito; Andrés Lanzós; Tina Uroda; Sunandini Ramnarayanan; Isabel Büchi; Taisia Polidori; Hugo Guillen-Ramirez; Ante Mihaljevic; Bernard Mefi Merlin; Lia Mela et al.
Source: Self-asserted source
Michaela Medova

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks

Molecular Cancer
2023-05-12 | Journal article
DOI: 10.1186/s12943-023-01775-1
Part of ISSN: 1476-4598
Contributors: Lusine Hovhannisyan; Carsten Riether; Daniel M. Aebersold; Michaela Medová; Yitzhak Zimmer
Source: Self-asserted source
Michaela Medova

In Reply to Raaijmakers et al.

International Journal of Radiation Oncology*Biology*Physics
2023-03 | Journal article
DOI: 10.1016/j.ijrobp.2022.11.019
Part of ISSN: 0360-3016
Contributors: Fabio Dennstädt; Markus Glatzer; Michaela Medová; Paul Martin Putora
Source: Self-asserted source
Michaela Medova

Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review

Biomedicines
2022-12 | Journal article | Author
DOI: 10.3390/biomedicines10123288
Contributors: Daniel H. Schanne; Alexander Koch; Olgun Elicin; Roland Giger; Michaela Medova; Yitzhak Zimmer; Daniel M. Aebersold
Source: check_circle
Multidisciplinary Digital Publishing Institute

An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies.

Cellular and molecular life sciences : CMLS
2022-12-10 | Journal article
DOI: 10.1007/s00018-022-04634-2
PMID: 36494469
PMC: PMC9734221
Contributors: Orlando E; Medo M; Bensimon A; Quintin A; Riedo R; Roth SM; Riether C; Marti TM; Aebersold DM; Medová M et al.
Source: Self-asserted source
Michaela Medova
grade
Preferred source (of 2)‎

Beyond keratinocyte differentiation: emerging new biology of small proline-rich proteins.

Trends in cell biology
2022-09-01 | Journal article
DOI: 10.1016/j.tcb.2022.08.002
PMID: 36057494
Contributors: Zabini A; Zimmer Y; Medová M
Source: Self-asserted source
Michaela Medova

Parameters of the Lyman Model for Calculation of Normal-Tissue Complication Probability: A Systematic Literature Review.

International journal of radiation oncology, biology, physics
2022-08-24 | Journal article
DOI: 10.1016/j.ijrobp.2022.08.039
PMID: 36029911
Contributors: Fabio Dennstädt; Medová M; Putora PM; Glatzer M
Source: Self-asserted source
Michaela Medova

Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury.

Cell death & disease
2021-04-06 | Journal article | Author
DOI: 10.1038/s41419-021-03654-3
PMID: 33824326
PMC: PMC8024273
Contributors: Nicolas Melin; Daniel Sanchez-Taltavull; Fahrner R; Keogh A; Michel Dosch; Büchi I; Zimmer Y; Michaela Medova; Guido Beldi; Aebersold DM et al.
Source: Self-asserted source
Michaela Medova

The LIM Protein Ajuba Augments Tumor Metastasis in Colon Cancer

Cancers
2020-07 | Journal article | Author
DOI: 10.3390/cancers12071913
Contributors: Noëlle Dommann; Daniel Sánchez-Taltavull; Linda Eggs; Fabienne Birrer; Tess Brodie; Lilian Salm; Felix Alexander Baier; Michaela Medova; Magali Humbert; Mario P. Tschan et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Deciphering MET‐dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics

Molecular Oncology
2020-06 | Journal article | Author
DOI: 10.1002/1878-0261.12696
Part of ISSN: 1574-7891
Part of ISSN: 1878-0261
Contributors: Ariel Bensimon; Jonas P. Koch; Paola Francica; Selina M. Roth; Rahel Riedo; Astrid A. Glück; Eleonora Orlando; Andree Blaukat; Daniel M. Aebersold; Yitzhak Zimmer et al.
Source: Self-asserted source
Michaela Medova

Enhancing CRISPR deletion via pharmacological delay of DNA-PK

2020-02 | Other
OTHER-ID:

PPR113052
Contributors: Bosch N; Medová M; Esposito R; Pulido-Quetglas C; Zimmer Y; Johnson R
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

MET targeting: time for a rematch.

Oncogene
2020-02 | Journal article
PMID: 32034310
Contributors: Koch JP; Aebersold DM; Zimmer Y; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data.

BMC bioinformatics
2019-11 | Journal article
PMID: 31706265
PMC: PMC6842221
Contributors: Medo M; Aebersold DM; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.

Molecular cancer therapeutics
2019-11-19 | Journal article | Author
DOI: 10.1158/1535-7163.mct-18-1274
PMID: 31744898
Contributors: Nisa L; Francica P; Roland Giger; Matúš Medo; Olgun Elicin; Friese-Hamim M; Wilm C; Stroh C; Bojaxhiu B; Quintin A et al.
Source: Self-asserted source
Michaela Medova

A Comparative Analysis of Individual RAS Mutations in Cancer Biology.

Frontiers in oncology
2019-10 | Journal article
PMID: 31681616
PMC: PMC6813200
Contributors: Muñoz-Maldonado C; Zimmer Y; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma.

Cell death & disease
2019-10 | Journal article
PMID: 31582741
PMC: PMC6776510
Contributors: Gavini J; Dommann N; Jakob MO; Keogh A; Bouchez LC; Karkampouna S; Julio MK; Medova M; Zimmer Y; Schläfli AM et al.
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET activating mutations-driven models.

The FEBS journal
2019-04-16 | Journal article
DOI: 10.1111/febs.14852
PMID: 30993872
Source: Self-asserted source
Michaela Medova

Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase

2019-02 | Journal article
DOI: 10.1016/j.canlet.2018.12.001
Part of ISSN: 0304-3835
Source: Self-asserted source
Michaela Medova

Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.

Molecular cancer research : MCR
2018-08-14 | Journal article
DOI: 10.1158/1541-7786.mcr-18-0056
PMID: 30108165
Source: Self-asserted source
Michaela Medova
grade
Preferred source (of 2)‎

Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Oncogene
2018-05-02 | Journal article
DOI: 10.1038/s41388-018-0256-6
PMID: 29717265
Source: Self-asserted source
Michaela Medova

OMIP-045: Characterizing human head and neck tumors and cancer cell lines with mass cytometry.

Cytometry. Part A : the journal of the International Society for Analytical Cytology
2018-04-12 | Journal article
DOI: 10.1002/cyto.a.23336
PMID: 29648681
Source: Self-asserted source
Michaela Medova
grade
Preferred source (of 2)‎

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.

Molecular cancer
2018-02 | Journal article
DOI: 10.1186/s12943-018-0798-9
PMID: 29455660
PMC: PMC5817809
Contributors: Poliaková M; Aebersold DM; Zimmer Y; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.

Molecular cancer
2017-05-22 | Journal article | Author
DOI: 10.1186/s12943-017-0660-5
PMID: 28532501
PMC: PMC5441085
Contributors: Nisa L; Pascal Häfliger; Poliaková M; Roland Giger; Francica P; Aebersold DM; Roch-Philippe Charles; Zimmer Y; Michaela Medova
Source: Self-asserted source
Michaela Medova
grade
Preferred source (of 2)‎

Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cells.

2017-02 | Journal article
DOI: 10.1038/srep41901
PMID: 28157203
PMC: PMC5291222
Contributors: Nita I; Hostettler K; Tamo L; Medová M; Bombaci G; Zhong J; Allam R; Zimmer Y; Roth M; Geiser T et al.
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer.

2017-02 | Journal article
DOI: 10.1016/j.bcp.2016.08.022
PMID: 27574725
Contributors: Francica P; Aebersold DM; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.

2016-11 | Journal article
DOI: 10.1158/1078-0432.ccr-15-2987
PMID: 27185371
Contributors: Francica P; Nisa L; Aebersold DM; Langer R; Bladt F; Blaukat A; Stroka D; Martínez MR; Zimmer Y; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Tepotinib. Selective MET receptor tyrosine kinase inhibitor, Treatment of lung and liver cancers

Drugs of the Future
2016-11 | Journal article
DOI: 10.1358/dof.2016.041.11.2555984
Source: Self-asserted source
Michaela Medova

Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches.

2015 | Journal article
DOI: 10.3390/cancers7020585
PMID: 25836654
PMC: PMC4491672
Contributors: Nisa L; Aebersold DM; Giger R; Caversaccio MD; Borner U; Medová M; Zimmer Y
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.

2015-09 | Journal article
PMID: 26358474
Contributors: Mikami K; Medova M; Nisa L; Francica P; Gluck AA; Tschan MP; Blaukat A; Bladt F; Aebersold DM; Zimmer Y
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

2015-08 | Journal article
DOI: 10.1016/j.molonc.2015.04.001
PMID: 25933688
Contributors: Leiser D; Medová M; Mikami K; Nisa L; Stroka D; Blaukat A; Bladt F; Aebersold DM; Zimmer Y
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer.

2015-07 | Journal article
PMID: 26413215
PMC: PMC4575919
Contributors: Piguet AC; Medová M; Keogh A; Glück AA; Aebersold DM; Dufour JF; Zimmer Y
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Interplay between receptor tyrosine kinases and hypoxia signaling in cancer.

2015-05 | Journal article
DOI: 10.1016/j.biocel.2015.02.018
PMID: 25747905
Contributors: Glück AA; Aebersold DM; Zimmer Y; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer.

2014-09 | Journal article
DOI: 10.1016/j.pharmthera.2014.04.005
PMID: 24786972
Contributors: Nisa L; Aebersold DM; Giger R; Zimmer Y; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.

2014-03 | Journal article
DOI: 10.1016/j.febslet.2013.12.025
PMID: 24440350
Contributors: Leiser D; Pochon B; Blank-Liss W; Francica P; Glück AA; Aebersold DM; Zimmer Y; Medová M
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects.

2013 | Journal article
DOI: 10.3390/cancers6010001
PMID: 24378750
PMC: PMC3980615
Contributors: Medová M; Aebersold DM; Zimmer Y
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.

2013-11 | Journal article
DOI: 10.1158/1535-7163.MCT-13-0151
PMID: 24061647
Contributors: Medová M; Pochon B; Streit B; Blank-Liss W; Francica P; Stroka D; Keogh A; Aebersold DM; Blaukat A; Bladt F et al.
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.

2013-02 | Journal article
DOI: 10.1016/j.bbrc.2012.12.120
PMID: 23313490
Contributors: Humbert M; Medová M; Aebersold DM; Blaukat A; Bladt F; Fey MF; Zimmer Y; Tschan MP
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks

International Journal of Cancer
2012-02-01 | Journal article
DOI: 10.1002/ijc.26058
Part of ISSN: 0020-7136
Contributors: Michaela Medová; Daniel M Aebersold; Yitzhak Zimmer
Source: Self-asserted source
Michaela Medova
grade
Preferred source (of 2)‎

MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest.

Genes & cancer
2010-10-01 | Journal article | Author
DOI: 10.1177/1947601910388030
PMID: 21779429
PMC: PMC3092265
Contributors: Michaela Medova; Aebersold DM; Blank-Liss W; Streit B; Matúš Medo; Stefan Aebi; Zimmer Y
Source: Self-asserted source
Michaela Medova

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.

2010-03 | Journal article
DOI: 10.1016/j.canlet.2009.08.017
PMID: 19783361
Contributors: Zimmer Y; Vaseva AV; Medová M; Streit B; Blank-Liss W; Greiner RH; Schiering N; Aebersold DM
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3beta.

2009-10 | Journal article
DOI: 10.1016/j.bbamcr.2009.08.002
PMID: 19682504
Contributors: Banz VM; Medová M; Keogh A; Furer C; Zimmer Y; Candinas D; Stroka D
Source: Self-asserted source
Michaela Medova via Europe PubMed Central

Coupling of mutated Met variants to DNA repair via Abl and Rad51.

Cancer research
2008-07-01 | Journal article | Author
DOI: 10.1158/0008-5472.can-08-1269
PMID: 18632630
Contributors: Ganapathipillai SS; Michaela Medova; Aebersold DM; Manley PW; Berthou S; Streit B; Blank-Liss W; Greiner RH; Barbara Rothen-Rutishauser; Zimmer Y
Source: Self-asserted source
Michaela Medova

Influence of ionic strength, pH and aptamer configuration for binding affinity to thrombin.

Bioelectrochemistry
2007-01 | Journal article
DOI: 10.1016/j.bioelechem.2006.03.012
Source: Self-asserted source
Michaela Medova

Peer review (5 reviews for 3 publications/grants)

Review activity for Cellular and molecular life sciences (3)
Review activity for npj precision oncology. (1)
Review activity for Radiation oncology. (1)
How many people are using ORCID?